MASSACHUSETTS Lawyers Weekly

GO TO LAWYERS

Life Sciences - 2026

WESLEY C. HOLMES

OFFICE MANAGING PARTNER

Latham & Watkins



With 20 years' experience advising companies and banks on some of their most complex and sophisticated transactions, Wesley C. Holmes has built a reputation as a leading health care lawyer — not only in Boston, but in the U.S. and globally — and one who invests himself in the long-term success of the client.

Holmes has built his reputation by helping clients achieve their most ambitious objectives on a broad range of transactions, including public securities offerings, high-yield debt offerings, M&A finance, private and venture offerings.

In the process, he has significantly expanded Latham's Boston office's health care and life sciences capital markets practice, bringing multiple lateral partners and associates into its ranks and growing its market share, even throughout the pandemic.

Holmes's noteworthy transactions include leading a team that represented P3 Health Partners, a patient-centered and physician-led population health management company, in its completed business combination with publicly traded Foresight Acquisition Corp.

He also led the team that represented Altaris Capital in the sale of its portfolio company. BK Medical, a designer and manufacturer of medical devices, to GE Healthcare, a subsidiary of General Electric.

That acquisition, reportedly GE's largest under Larry Culp since taking over as CEO in 2018, enabled the company to expand its ultrasound business from diagnostics to surgical imaging.

Holmes also represented Rapid Micro Biosystems, an innovative Massachusetts-based life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of health care products, in its initial public offering of more than 9 million shares of Class A Common Stock listed on Nasdaq.

In addition, Holmes led the team that represented Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world's most prevalent eye diseases, in its $240 million IPO on Nasdaq.

Holmes was a 2025 finalist for New England Legal Awards' Regional Managing Partner of the Year Award.